Eli Lilly Loses Some Luster
October 10, 2017 at 10:20 AM EDT
Eli Lilly's shares are getting hit by the combined pressure from an analyst downgrade and disappointing clinical trial results for a new cancer drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|